NCT05929495 is a Phase 2 clinical trial of Metformin in Glioblastoma, IDH-wildtype, sponsored by University of Milano Bicocca.

Who is sponsoring NCT05929495?

NCT05929495 is sponsored by University of Milano Bicocca.

What drugs are being tested in NCT05929495?

Interventions in NCT05929495: Metformin.

What condition does NCT05929495 study?

NCT05929495 studies Glioblastoma, IDH-wildtype, Metformin, Malignancies.

Is NCT05929495 still recruiting?

NCT05929495 is currently recruiting now. Last updated 25 July 2025.

Last reviewed 2025-07-25 · How we verify

NCT05929495

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma

Recruiting now Phase 2 Last updated 25 July 2025

What this trial tests

Phase 2 trial testing Metformin in Glioblastoma, IDH-wildtype in 25 participants. Currently enrolling.

Timeline

12 February 2024

Primary endpoint
1 January 2026

1 January 2026

Quick facts

Lead sponsor	University of Milano Bicocca
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	12 February 2024
Primary completion	1 January 2026
Estimated completion	1 January 2026
Sites	1 location across Italy

Drugs / interventions tested

Metformin (metformin) — full drug profile →

Conditions studied

Glioblastoma, IDH-wildtype — all drugs for Glioblastoma, IDH-wildtype →
Metformin — all drugs for Metformin →
Malignancies — all drugs for Malignancies →

Sponsor

University of Milano Bicocca

Who can join

18 and older, any sex, with Glioblastoma, IDH-wildtype or Metformin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies. This is a nationwide single-center phase II drug clinical trial with an approximate duration of 32 months. The clinical trial will be single-arm to evaluate the biological activity and effects of metformin in combination with TMZ in patients with GBM.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Metformin: A Dual-Role Player in Cancer Treatment and Prevention.
Galal MA, Al-Rimawi M, Hajeer A, Dahman H, et al · · 2024 · cited 44× · PMID 38612893 · DOI 10.3390/ijms25074083
Drug Repurposing for Cancer Treatment: A Comprehensive Review.
Al Khzem AH, Gomaa MS, Alturki MS, Tawfeeq N, et al · · 2024 · cited 24× · PMID 39596504 · DOI 10.3390/ijms252212441
Advances in Anti-Cancer Drug Development: Metformin as Anti-Angiogenic Supplemental Treatment for Glioblastoma.
Shah S, Mansour HM, Aguilar TM, Lucke-Wold B. · · 2024 · cited 16× · PMID 38891882 · DOI 10.3390/ijms25115694
Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations.
Abecunas C, Kidd AD, Jiang Y, Zong H, et al · · 2024 · cited 6× · PMID 39305483 · DOI 10.1016/j.celrep.2024.114775
Metabolic adaptation of myeloid cells in the glioblastoma microenvironment.
Essakhi N, Bertucci A, Baeza-Kallee N, Colin C, et al · · 2024 · cited 4× · PMID 39763643 · DOI 10.3389/fimmu.2024.1431112
Targeting the Mitochondria in High-Grade Gliomas.
Sathe S, Li Q, Jung J, Wu J. · · 2025 · cited 2× · PMID 41008904 · DOI 10.3390/cancers17183062
Targeting tumor dormancy: the next frontier in gastrointestinal stromal tumor therapy.
Wu S, Liu H, Yin Y, Li J, et al · · 2026 · PMID 41955967 · DOI 10.1016/j.neo.2026.101306
Metformin Suppresses Glioblastoma Tumor Growth and Progression Through the AMPK/FoxO3a/Survivin Axis.
Cavaliere F, Pellegrino M, Cormace A, Spadafora S, et al · · 2026 · PMID 41677673 · DOI 10.3390/cells15030310

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Glioblastoma, IDH-wildtype

Currently open trials in the same condition.

NCT06419946 — Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma · Phase 3 · recruiting
NCT06327451 — Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma · Phase 2 · recruiting
NCT06418113 — Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma · Phase 1 · recruiting
NCT05941234 — Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma · NA · recruiting
NCT06047379 — Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · Phase 1, PHASE2 · recruiting

Other University of Milano Bicocca trials

Trials by the same sponsor.

NCT07257705 — Pilot Trial of a Clinical Decision-Support App for Managing Emergencies Among Clinicians in a Rural Ugandan Hospital · NA · completed
NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07407608 — ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07424066 — Non-invasive Vibratory Stimulation of the Knee Muscles for the Improvement of the Somatosensory Input and Motor Performa · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05929495 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Milano Bicocca
Last refreshed: 25 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05929495.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing